A sensitive immunochromatographic assay using gold nanoparticles for the semiquantitative detection of prostate-specific antigen in serum

• Published in: Nanobiotechnology Vol. 2; no. 3-4; pp. 79 - 86
• Main Authors: Nagatani, Naoki, Yuhi, Teruko, Chikae, Miyuki, Kerman, Kagan, Endo, Tatsuro, Kobori, Yoshitomo, Takata, Masayuki, Konaka, Hiroyuki, Namiki, Mikio, Ushijima, Hiromi, Takamura, Yuzuru, Tamiya, Eiichi
• Format: Journal Article
• Language: English
• Published: Dordrecht Springer Nature B.V 01.09.2006
• Subjects: Antigens; Enzymes; Immunoassay; Medical screening; Nanoparticles; Prostate cancer
• ISSN: 1551-1286; 1551-1294
• DOI: 10.1007/BF02697262

In prostate cancer screening, prostate-specific antigen (PSA) has been utilized as a valuable biomarker. There are routinely used procedures based on enzyme-linked immunosorbent assay (ELISA) for PSA detection. The procedures based on ELISA, however, are time consuming, complicated, and costly. We have developed a rapid, very simple, cost effective and sensitive immunochromatographic assay using gold nanoparticles and evaluated its applications for first screening of prostate cancer in serum samples. The sensitive immunochromatographic assay requires only 40 μL of the serum sample. The assay used is rapid and simple, that it totally takes approx 15 min to complete. The method for sensitive immunochromatographic assay has the other advantage of decreasing the antibody concentration that is used for the test line. In this study, we show the advantage to decrease the antibody concentration and the evaluation of our sensitive immunochromatographic assay for the semiquantitative detection of PSA in serum. The results obtained from 163 serum samples using sensitive immunochromatographic assay are compared with the results obtained using the chemiluminescent enzyme immunoassay (CLEIA) and normal immunochromatographic assay. The results obtained in the sensitive immunochromatographic assay correlated well with the values obtained in CLEIA. We concluded that our sensitive immunochromatographic assay is applicable to the first screening test for the diagnosis of prostate cancer. Our developed sensitive immunochromatographic assay is a promising candidate for diagnosis or research use, which may become commercially available in the near future.[PUBLICATION ABSTRACT]